https://www.live-feeds.com/feed/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-trialhttps://www.live-feeds.com/feed/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-trial#u62414Wed, 09 Sep 2026 06:35:19 +0000Novartis reported that its experimental drug pelacarsen failed its primary endpoint in the Lp(a)HORIZON Phase 3 trial. Although the drug lowered lipoprotein(a) levels in over 8,000 patients, it did not reduce the risk of strokes, heart attacks, or cardiovascular death. The result triggered a sharp market decline for Novartis and Ionis, and weighed on Amgen shares. Investors are now questioning the efficacy of the entire Lp(a)-targeting drug class despite some companies reporting separate promising results.Why it mattersLp(a) is a genetically driven risk factor for heart disease. This trial foc https://www.live-feeds.com/feed/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-trialhttps://www.live-feeds.com/feed/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-trial#u60375Mon, 07 Sep 2026 18:16:40 +0000Novartis announced that its experimental drug pelacarsen failed to meet its primary endpoint in the Lp(a)HORIZON Phase 3 trial. The study aimed to reduce the risk of cardiovascular events in patients with established cardiovascular disease and elevated Lp(a) levels of 70mg/dL or above. While the drug successfully lowered the genetically driven risk factor, it did not reduce cardiovascular events compared to a placebo. The failure has triggered a selloff of Novartis and Ionis shares and raised broader questions regarding the efficacy of Lp(a)-targeting therapies.Why it mattersLp(a) is a genetic